| 0.3927 0.105 (36.35%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.61 |
1-year : | 0.8 |
| Resists | First : | 0.52 |
Second : | 0.68 |
| Pivot price | 0.3 |
|||
| Supports | First : | 0.27 | Second : | 0.22 |
| MAs | MA(5) : | 0.3 |
MA(20) : | 0.31 |
| MA(100) : | 1.83  |
MA(250) : | 6.32 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 22.1 |
D(3) : | 15.9 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 25.6 | Low : | 0.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ACON ] has closed above the upper band by 32.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 91.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.69 - 0.69 | 0.69 - 0.7 |
| Low: | 0.29 - 0.29 | 0.29 - 0.29 |
| Close: | 0.39 - 0.39 | 0.39 - 0.4 |
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Mon, 26 Feb 2024
Why Is Aclarion (ACON) Stock Down 19% Today? - InvestorPlace
Mon, 26 Feb 2024
Aclarion seeks to raise $3M through penny-stock sale – BizWest - BizWest
Tue, 30 Jan 2024
Aclarion, Inc. Strikes Key Stock-for-Debt Agreement - TipRanks.com - TipRanks
Fri, 26 Jan 2024
Aclarion Inc (ACON) is higher by 81.28% Friday In Premarket Trading - InvestorsObserver
Fri, 26 Jan 2024
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ... - Benzinga
Fri, 26 Jan 2024
Why Is Aclarion (ACON) Stock Up 109% Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 1.93e+006 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 159 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.71e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 163.6 % |
| Return on Equity (ttm) | -113.5 % |
| Qtrly Rev. Growth | 75400 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -705.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 61970 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|